Johannesburg, 29 August 2025 – As of September 2025, Aspen Pharmacare will undertake the distribution of selected Boehringer Ingelheim prescription medicines across South Africa. This partnership represents a significant step towards ensuring that more patients gain timely access to the treatments they need, helping improve health outcomes today and for generations to come.
“Our priority is always patients. Partnering with Aspen means we can bring our innovative medicines to people faster, addressing urgent needs in cardio-renal-metabolic and lung diseases as well as stroke. As a company, we focus on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Together, we are not only improving access today but also transforming the lives of future generations across South Africa,” says Dr Anthony Lauw, General Manager and Head of Human Pharma, Boehringer Ingelheim Southern Africa.
Commenting on the partnership, Heinz Schütte, Aspen Regional CEO South Africa Commercial said: “For us, this collaboration is about putting patients first. By leveraging our reach and expertise in South Africa, we can ensure that Boehringer Ingelheim’s innovative therapies are accessible to more people, when and where they need them. This is an important milestone in our ongoing mission to improve health outcomes across the country.”
Boehringer Ingelheim, an independent and family-owned company, takes a long-term view of healthcare, investing heavily in research and development to deliver innovative therapies that address unmet medical needs.
This agreement was approved by the South African Competition Tribunal on 15 July 2025, following a recommendation from the Competition Commission.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim – Life Forward | Boehringer Ingelheim.
Aspen Pharmacare
Headquartered in Durban, South Africa, Aspen is a leading global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. Aspen improves the health of patients in more than 115 countries through its high quality, affordable medicines. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals, comprising Prescription, Over-the-counter and Injectable Brands. Aspen has more than 9100 employees and has 65 established business operations in over 50 countries. The Group operates 23 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. Its manufacturing capabilities are scalable to demand and cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. For more information visit www.aspenpharma.com.